(R)-Ketorolac
Based on 2 publication(s) in Google Scholar
(R)-Ketorolac is an orally active Cdc42 and Rac1 inhibitor. (R)-Ketorolac inhibits GTPase. (R)-Ketorolac alters ovarian cancer cell behaviors critical for invasion and metastasis. (R)-Ketorolac ameliorates cancer-associated cachexia.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.35%
- CAS. Nr.: 66635-93-6
- Formel: C15H13NO3
- Molecular Weight:255.27
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
GPCR/G Protein Compound Library
HY-L006
-
Immunology/Inflammation Compound Library
HY-L007
-
Kinase Inhibitor Library
HY-L009
-
MAPK Compound Library
HY-L010
-
Anti-Cancer Compound Library
HY-L025
-
Oxygen Sensing Compound Library
HY-L045
-
Ferroptosis Compound Library
HY-L051
-
Orally Active Compound Library
HY-L061
-
Glutamine Metabolism Compound Library
HY-L064
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Angiogenesis-Related Compound Library
HY-L088
-
Anti-Liver Cancer Compound Library
HY-L101
-
Anti-Colorectal Cancer Compound Library
HY-L103
-
Membrane Protein-targeted Compound Library
HY-L149
-
Membrane Receptor-targeted Compound Library
HY-L150
-
Anti-Hematopathy Compound Library
HY-L171
-
Anti-Ovarian Cancer Compound Library
HY-L173
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Cell Proliferation Compound Library
HY-L201
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
-
Lactylation Compound Library
HY-L249
-
3D Diverse Fragment Library
HY-L903
Publications Citing Use of MedChemExpress (MCE) (R)-Ketorolac
More
Customer Validation & Images
-
Flow Cytometry
Biologische Aktivität
(R)-Ketorolac substantially inhibits growth factor dependent activation of Cdc42 and Rac1 in a dose-dependent manner with an EC50 value of 2.577 μM for Cdc42 and 0.587 μM for Rac1 in SKOV3ip cells[2].
(R)-Ketorolac (1-10 μM) decreases numbers length of filopodia in SKOV3ip cells and reduces SKOV3ip cells adherence to both fibronectin and collagen[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C26 tumour-bearing mice[3]
-
Dosage:2 mg/kg
-
Administration:Oral gavage (p.o.), every day after cachexia onset
-
Result:Prolonged survival and alleviates C26-induced weight loss independent of tumour growth and food intake.
Showed a tumour weight of 0.7 g and a weight loss of 0.61 g.
Did not affect C26-associated hepatosplenomegaly and splenic lymphocyte numbers.
Prevented C26-induced T-lymphopenia.
Chemical Information
-
CAS. Nr. 66635-93-6
-
Appearance Solid
-
Molecular Weight 255.27
-
Formel C15H13NO3
-
Color White to off-white
-
SMILES
O=C(C1=CC=CC=C1)C2=CC=C3N2CC[C@H]3C(O)=O
-
Synonyms
(+)-Ketorolac
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
Endocrine therapy reprogramming of breast cancer facilitates metastatic escape via upregulation of P-Rex1/Rac1 signalling. [Abstract]2026 May 11;17(1):3042. PMID: 42115169 -
J Biol Chem
Cell aggregation activates small GTPase Rac1 and induces CD44 cleavage by maintaining lipid rafts integrity. [Abstract]2023 Dec;299(12):105377. PMID: 37866630
(R)-Ketorolac purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2023 Dec;299(12):105377. [Abstract]
R-Ketorolac (1-100 μM; 48 h). MDA-MB-231 cells are cultured in poly-HEMA-coated dishes in the presence or absence of R-Ketorolac for 48 h, and the cells are collected for anoikis analysis by Annexin V/PI staining. Control and 1 μM R-Ketorolac (R-Ket)-treated groups are used for quantification, and graph data are presented as mean ± SD (n = 3).
Lösungsmittel & Löslichkeit
DMSO : ≥ 100 mg/mL (391.74 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (19.59 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Handley DA, et al. Preclinical enantioselective pharmacology of (R)- and (S)- ketorolac. J Clin Pharmacol. 1998 Feb;38(2S):25S-35S. [Content Brief]
[2]. Guo Y, Kenney SR, Muller CY, et al. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol Cancer Ther. 2015;14(10):2215-2227. [Content Brief]
[3]. Chrysostomou SE, et al. R-ketorolac ameliorates cancer-associated cachexia and prolongs survival of tumour-bearing mice. J Cachexia Sarcopenia Muscle. 2024 Apr;15(2):562-574. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.9174 mL | 19.5871 mL | 39.1742 mL | 97.9355 mL |
| 5 mM | 0.7835 mL | 3.9174 mL | 7.8348 mL | 19.5871 mL | |
| 10 mM | 0.3917 mL | 1.9587 mL | 3.9174 mL | 9.7936 mL | |
| 15 mM | 0.2612 mL | 1.3058 mL | 2.6116 mL | 6.5290 mL | |
| 20 mM | 0.1959 mL | 0.9794 mL | 1.9587 mL | 4.8968 mL | |
| 25 mM | 0.1567 mL | 0.7835 mL | 1.5670 mL | 3.9174 mL | |
| 30 mM | 0.1306 mL | 0.6529 mL | 1.3058 mL | 3.2645 mL | |
| 40 mM | 0.0979 mL | 0.4897 mL | 0.9794 mL | 2.4484 mL | |
| 50 mM | 0.0783 mL | 0.3917 mL | 0.7835 mL | 1.9587 mL | |
| 60 mM | 0.0653 mL | 0.3265 mL | 0.6529 mL | 1.6323 mL | |
| 80 mM | 0.0490 mL | 0.2448 mL | 0.4897 mL | 1.2242 mL | |
| 100 mM | 0.0392 mL | 0.1959 mL | 0.3917 mL | 0.9794 mL |
(R)-Ketorolac Related Classifications
HY-B0580B Related Classifications
Powered by Bioz